Dainippon Sumitomo to buy U.S. drugmaker Sepracor for $2.6 bil.

Dainippon Sumitomo to buy U.S. drugmaker Sepracor for $2.6 bil.

TOKYO, Japan - Dainippon Sumitomo Pharma Co. President Masayo Tada speaks about the company's plan to buy U.S. pharmaceutical maker Sepracor Inc. for about $2.6 billion (around 240 billion yen) at a news conference in Tokyo on Sept. 3. Sepracor will become a wholly owned unit of Dainippon Sumitomo Pharma America Holdings Inc., a U.S. subsidiary of the Japanese drugmaker.

  • Product Code
  • ILEA001136765
  • Registered date
  • 2009/9/03 00:00:00
  • Credit
  • Kyodo / Kyodo News Images
  • Media source
  • 2009 Kyodo News
  • Media size
  • 1303 × 1745 pixel
  • Resolution
  • 240 dpi
  • Deployment size
  • 370.71(KB)*
  • Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos
    Novartis management replaced

    Novartis management replaced

    TOKYO, Japan - David Epstein (L), president of Swiss pharmaceutical giant Novartis speaks during a press conference in Tokyo on April 3, 2014. The Japanese sales arm of the company, Novartis Pharma K.K., announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors. At right is new Novartis Pharma K.K. President Dirk Kosche.
      Novartis management replaced

      Novartis management replaced

      TOKYO, Japan - David Epstein, president of Swiss pharmaceutical giant Novartis holds a press conference in Tokyo on April 3, 2014. The Japanese sales arm of the company, Novartis Pharma K.K., announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.
        Novartis management replaced

        Novartis management replaced

        TOKYO, Japan - Dirk Kosche, new president of Novartis Pharma K.K., speaks during a press conference in Tokyo on April 3, 2014. The Japanese sales arm of Swiss pharmaceutical giant Novartis announced that its president, Yoshiyasu Ninomiya, and two other top executives have resigned to take responsibility for its employees' inappropriate involvement in a clinical study led by medical doctors.
          Takeda chief apologizes over data misuse in drug ad

          Takeda chief apologizes over data misuse in drug ad

          TOKYO, Japan - Takeda Pharmaceutical Co. President Yasuchika Hasegawa apologizes during a press conference in Tokyo on March 3, 2014, over an advertisement for the company's blood pressure-lowering drug that made it appear the product is more powerful in suppressing diseases than other medicines.
            Takeda chief apologizes over data misuse in drug ad

            Takeda chief apologizes over data misuse in drug ad

            TOKYO, Japan - Takeda Pharmaceutical Co. President Yasuchika Hasegawa apologizes during a press conference in Tokyo on March 3, 2014, over an advertisement for the company's blood pressure-lowering drug that made it appear the product is more powerful in suppressing diseases than other medicines.
              Japan Tobacco to undertake drastic restructuring

              Japan Tobacco to undertake drastic restructuring

              TOKYO, Japan - Japan Tobacco Co. Vice President Akira Saeki speaks at a news conference in Tokyo on Oct. 30, 2013, as the company said it will close four of its nine cigarette manufacturing-related factories in Japan and a vending machine production base, most of them in March 2015, and cut 1,600 jobs, or about 20 percent of the employees in its tobacco business, due to falling sales.
                Novartis scandal

                Novartis scandal

                TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, speaks in a press conference in Tokyo on Oct. 3, 2013. At right is Yoshiyasu Ninomiya, president of Novartis Pharma K.K., a Japanese unit of Novartis AG. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.
                  Novartis scandal

                  Novartis scandal

                  TOKYO, Japan - David Epstein (C), division head at Novartis AG, the Swiss-based pharmaceutical giant, and Yoshiyasu Ninomiya (R), president of Novartis Pharma K.K., a Japanese unit of Novartis AG, bow in apology during a press conference in Tokyo on Oct. 3, 2013. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.
                    Novartis division head Epstein

                    Novartis division head Epstein

                    TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, holds talks with Japanese Health, Labor and Welfare Minister Norihisa Tamura (R) at the ministry in Tokyo on Sept. 26, 2013. Tamura summoned Epstein and sharply criticized the firm for triggering a scandal involving Novartis Pharma K.K., the Japanese subsidiary of Novartis AG. The unit allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.
                      Novartis Pharma

                      Novartis Pharma

                      TOKYO, Japan - Yoshiyasu Ninomiya, president of Novartis Pharma K.K., attends a press conference in Tokyo on July 29, 2013. Novartis Pharma, a Japanese unit of Swiss drug company Novartis AG, said it has found no evidence a former employee manipulated or altered clinical research data for the drugmaker's Diovan blood pressure lowering drug.